Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
Background IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and huma...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2025-12-01
|
| シリーズ: | Renal Failure |
| 主題: | |
| オンライン･アクセス: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2449580 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|